Abstract 301P
Background
Cervical cancer is the most prevalent reproductive malignancy in women worldwide and estimated over 600,000 new cases and 340,000 deaths each year. Concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer. Despite the great improvement this strategy has achieved, nearly 30% of patients will suffer distant metastases and 70% of patients may experience local recurrence. The dominance of Lactobacillus in the vaginal microenvironment of healthy women helps to establish a physiological barrier on the vaginal surface, Microbial biomarkers are effective for predicting the nonresponse for immune checkpoint inhibitor administration. It is intriguing to explore the alteration of vaginal microbial community challenged by chemoradiotherapy, also whether microorganism(s) could be used as biomarkers to predict the responsiveness of chemoradiotherapy.
Methods
A total of 126 patients with IB-IVB cervical cancer who received chemoradiotherapy in our hospital were enrolled in this study. The sampling of vaginal microbiome was carried out as we previously described, both pre- and post-treatment of each patient. Bacterial genomic DNA was extracted and 16S rRNA was sequenced from their vaginal secretions, and the results were analyzed bioinformatically.
Results
We found that the structure and composition of the vaginal microbiome changed significantly before and after radiotherapy, and radiotherapy treatment significantly changed the structure of the microorganisms, destroyed their physiological functions and disrupted the homeostasis of the microbial community. At the same time, we found that the beneficial microbial community in the vaginal microbiome decreased significantly in the relapsing group compared with the non-relapsing group before and after radiotherapy, and the microbial function and community homeostasis were significantly reduced, suggesting an unhealthy vaginal microbiome in the relapsing group.
Conclusions
We have shown that C-reactive protein and disease stage and other factors and biomarkers (such as L. iners) are important factors in predicting the recurrence of cervical cancer patients after radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
Zhejiang medicine and health science and technology project.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract